Evaxion A/S announced on June 3, 2025, that it has received funding support from the Gates Foundation to explore design options for a new polio vaccine. This project aims to contribute to the global effort to eradicate poliomyelitis.
Evaxion will deploy its AI-Immunology platform to identify and combine various antigens to combat the polio virus. The goal is to design new antigen constructs that eliminate the use of live viruses in vaccine production, offering a safer alternative to current polio vaccines.
The grant from the Gates Foundation means there will be no financial cost for Evaxion for this project. This collaboration further validates the company's AI-Immunology platform and expands its infectious disease pipeline without impacting its operational spend.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.